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ARTICLE
Possible role of L-form switching in recurrent
urinary tract infection
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Robert Pickard3, Judith Hall4, Serge Mostowy 2, Phillip D. Aldridge 1 & Jeff Errington 1*
Recurrent urinary tract infection (rUTI) is a major medical problem, especially in the elderly
and inﬁrm, but the nature of the reservoir of organisms responsible for survival and reco-
lonisation after antibiotic treatment in humans is unclear. Here, we demonstrate the presence
of cell-wall deﬁcient (L-form) bacteria in fresh urine from 29 out of 30 older patients with
rUTI. In urine, E. coli strains from patient samples readily transition from the walled state to
L-form during challenge with a cell wall targeting antibiotic. Following antibiotic withdrawal,
they then efﬁciently transition back to the walled state. E. coli switches between walled and
L-form states in a zebraﬁsh larva infection model. The results suggest that L-form switching is
a physiologically relevant phenomenon that may contribute to the recurrence of infection in
older patients with rUTI, and potentially other infections.
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Urinary tract infection (UTI) is a major cause of humandisease costing an estimated $1.6 billion per year in theUnited States1. Antibiotics are routinely used either to
treat acute episodes or prevent recurrence; however, they occa-
sionally fail to resolve the infection2,3. Recurence can be due to
reinfection or persistence of bacteria. Bacterial survival during
antibiotic treatment is generally thought to be facilitated by the
formation of quiescent intracellular reservoirs of persister cells
in the epithelium of the bladder4,5. Following antibiotic with-
drawal, the bacteria can resume replication, causing full-blown
infection4,5.
Bacterial cells are normally surrounded by a highly conserved
structure called the cell wall. This layer, composed of pepti-
doglycan, deﬁnes their shape, facilitates regular division and
protects from environmental factors, including changes in
osmolarity6. Cell-wall components are recognised by the immune
system and act as key indicators of infection7. The cell wall is also
a target for immune effectors, such as lysozyme, as well as for
some of our best and most commonly used antibiotics, particu-
larly β-lactams, such as penicillins and cephalosporins7,8.
Several scientiﬁc reports from the 1960s to 1980s suggested
that bacteria causing rUTI might survive treatment with cell-wall-
speciﬁc antibiotics by adopting a cell-wall-deﬁcient or L-form
state9–14. However, these reports were mainly unconvincing,
primarily due to the lack of molecular diagnostic tools14. Also, L-
forms are almost completely overlooked in clinical settings
because routine microbiological culture media are hypotonic and
do not support L-form growth. We recently demonstrated that
the L-form state can be induced by cells of the immune system in
tissue culture, as well as in an animal model, rendering the bac-
teria resistant to cell-wall-targeting antibiotics8. In this report we
show that L-forms are prevalent in older individuals suffering
from rUTI. Furthermore, we demonstrate, in both urine and
transparent zebraﬁsh larvae, that E. coli strains isolated from
these older patients can readily be induced to switch into the
L-form state, to survive and divide, and then efﬁciently switch
back into the walled state, potentially providing a route to the
recurrence of infection.
Results
L-forms frequently occur in elderly rUTI patients. In a study
described in detail elsewhere, 30 elderly patients suffering from
rUTI donated samples of urine every 2 weeks over a period of
6 months, generating a bank of 360 samples15. Ability to pass
through 0.45 μm cut off ﬁlters, which block the passage of walled
forms of pathogens, has been used to detect L-forms in various
settings16–19. A portion (2 ml) of each urine sample was ﬁltered
into semi-liquid osmoprotective media and incubated for up to
1 month. In many of the samples (Fig. 1a; Supplementary Fig. 1),
growth detectable by eye appeared within 1–2 weeks, with some
appearing after 3 days. Microscopically the bacteria resembled
rods or cocci, which most likely originated from L-forms that
passed through the ﬁlter, reverted to the walled state19 and
resumed division by conventional binary ﬁssion (see also below).
It is possible that immune factors or antibiotics which induced
those L-forms in vivo, were sufﬁciently diluted or inactivated
following ﬁltration, which allowed bacteria to rebuild the wall.
Given the slow emergence of growth it is improbable that this
originated from passage of walled bacteria through damaged ﬁl-
ters. Also, given the heavy bacterial load in most samples (typi-
cally around 103–105 viable bacteria per ml15), ﬁlter breakage
would have led to much higher rates and levels of growths in the
cultures than was seen. In control experiments cultures of walled
E. coli did not detectably pass through the ﬁlters (which are
generally used to sterilise solutions that cannot be autoclaved).
Also, the recovery of E. coli L-forms (strain BW25113, induced
under laboratory conditions) after ﬁltration was inefﬁcient
(~41%) (Fig. 1a L), probably because most of the cells burst or
were otherwise damaged by pressure and or torinal stress during
ﬁltration, so the number of positive samples was probably
underestimated.
Sixty one percent of bacteria recovered after passage through
the ﬁlter were identiﬁable as E. coli by 16S ribosomal sequencing;
the remainder were mainly common UTI organisms, such as
Enterococcus spp, Klebsiella spp, or Proteus spp (Supplementary
Fig. 1B, Supplementary data 1)20. Multiple positive samples from
the same patient usually contained bacteria of the same species
(Fig. 1a).
We also examined all of the fresh urine samples directly by
phase contrast microscopy. Although many classical rods and
cocci were evident, especially in samples that did not coincide
with antibiotic treatment of the patient, we also frequently
detected polymorphic entities resembling L-forms, usually
present side by side with walled bacteria. With one exception
(patient UTI562), we found L-form-like structures in at least one
of the 12 samples donated by each patient (Fig. 1b).
Figure 2a–h shows representative examples of L-form-like
structures observed in the urine samples. Spherical entities of
various sizes, occasionally associated in bundles characteristic
of dividing L-forms, were frequent, either suspended in urine
(Fig. 2a, b) or associated with eukaryotic cells (Fig. 2c, d,
magenta arrows). Occasionally, cells with phase pale crescent
shaped bulges, which are typical of Gram-negative L-forms
(probably due to local separation of inner and outer
membranes) were observed (Fig. 2e, f, magenta arrows). What
appeared to be intermediate stages between L-forms and walled
bacteria were also frequently detected (Fig. 2f, g, magenta
arrows). Sporadically, we observed spherical objects with
internal membrane vesicles, which are characteristic of large
L-forms (Fig. 2h, magenta arrow).
To conﬁrm that the observed L-form-like objects were of
bacterial rather than human origin (e.g. apoptotic bodies or
various granules) we ﬁxed 10 randomly selected samples of the
urine and stained them with DAPI, which binds to DNA
indiscriminately of origin, and with a ﬂuorescently labelled
oligonucleotide probe that hybridises with bacterial 16S rRNA
transcripts (BAC 16S). Figure 2i–k contains typical examples of
the results obtained. Figure 2i shows that polymorphic structures
reminiscent of L-forms observed in the samples (magenta arrow)
stained both with DAPI and the BAC 16S probe, just like rod-
shaped (walled) bacteria. Occasionally we observed structures
that stained only with DAPI indicative of eukaryote rather than
bacterial origin (Fig. 2i, blue arrow). An example in Fig. 2k shows
that the BAC 16S probe stained the bacteria but not human cell
components. Crucially, in the FISH probed samples, virtually all
of the objects (~99%) that looked like L-forms stained positively
with the BAC 16S probe (Fig. 2i, j), conﬁrming the bacterial
origin of the observed polymorphic structures.
Overall, L-forms were detected by microscopy or ﬁltration in
46% of collected samples (Fig. 1a, b). Even though accurate
quantitation of the microscopic samples was difﬁcult, we
nonetheless readily detected L-form-like objects in samples
derived from 20 µl of urine, and so we estimate that their
frequency ranged from about 102 to 104/ml.
L-forms provide a route for antibiotic evasion. The fact that L-
forms are completely resistant to antibiotics targeting the cell wall
has been highlighted as contributing to the survival of bacteria
during treatment9–14. We chose samples from patient UTI343 for
further detailed analysis because the patient had been treated with
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phosphomycin (donation 6), which we have shown previously to
actively promote L-form switching and proliferation21,22. A sig-
niﬁcant viable bacterial load (>1 × 105) was detected by standard
culture methods in all urine samples except from some in periods
when the patient was being treated with antibiotics (Table 1).
Multi-locus sequence typing (MLST) of cultured organisms
revealed that the samples predominantly contained a common
uropathogenic E. coli strain classiﬁed as type ST14423 (Supple-
mentary data 1). Importantly, the same organisms were detected
by conventional culture and after ﬁltration, consistent with the
idea that the organisms exist in both forms in the patient. The
routine culture load was reduced 10-fold at ﬁrst donation when
the patient was treated with amoxicillin. In sample donations 5
and 11 when the patient was being treated with cephalexin, a
different E. coli strain, less commonly implicated in UTI, referred
to as ST78224 (Supplementary data 1), became apparent but
ST144 was also detected. The ratio of ST144 to ST782 isolates
detected in donations 5 and 11 was 1/5 and 1/2, respectively,
based on 20 colonies screened. The viable bacterial load was
reduced on those days to 300 and 5.6 × 104/ml, respectively. A
total of ﬁve samples contained bacteria that went through the
ﬁlter, including on two occasions when the patient was being
treated with cephalexin. No E. coli strains were detected by
standard culture or ﬁltration experiments in donation 6, when the
patient was being treated with phosphomycin. However, L-forms
were detected on that day by microscopy and unlike other sam-
ples (Fig. 3a), there were no rod-shaped bacteria among
the potential L-forms (Figure 3b, c). The bacterial identity of
these L-form-like objects was veriﬁed by FISH (Fig. 3). Notably,
the urinary bacterial load returned to signiﬁcance (>1 × 105/ml)
after the treatment was concluded and the strains associated with
the relapse were ST144 and ST782.
Prevalence of L-forms in patients with recurrent UTls assessed by microscopy
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UTI patient identifier
Staphylococcus Klebsiella Pseudomonas Proteus Streptococcus Enterocbacter Enterococcus E.coli
531 536 562 569 675 726 755 781 834 840 891 899 824 966 974
100 115 138 139 218 236 266 337 343 365 376 383 414 468 524
UTI patient identifier
531 536 562 569 675 726 755 781 834 840 891 899 824 966 974
Fig. 1 Prevalence of L-forms in older patients with recurrent UTIs. a Samples assessed by ﬁltration. Each of the 30 recruited patients (X axis) donated a
total of 12 samples over the period of 6 months (Y axis). Samples which contained ﬁlterable bacteria (some of which were also observed by microscopy),
are symbolised by columns marked with solid colour (a). Various colours represent species of the ﬁltered bacteria identiﬁed by 16S sequencing. W stands
for a negative control in which 12 samples of laboratory BW25113 E. coli walled bacteria were passed through the 0.45 µm cut off ﬁlter onto osmoprotective
media. L stands for a positive control where 12 samples of laboratory E. coli BW25113 L-form bacteria were ﬁltered. b Samples assessed by phase contrast
microscopy. Samples positive for L-form-like structures when assessed by microscopy are represented by grey, dashed columns
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E. coli switches between L-form and walled states. Transition
from the walled state to the L-form has been shown for a wide
range of bacteria but usually L-form growth is much slower than
that of walled bacteria and requires osmoprotective conditions14.
We have recently shown that immune effectors such as lysozyme
can induce an L-form switch8. Furthermore, certain antibiotics
that interfere speciﬁcally with cell-wall precursor synthesis, such
as phosphomycin or D-cycloserine, can also induce L-forms21,22.
Given that L-form-like bacteria were found in many of the patient
samples, it was important to determine whether these bacteria are
capable of an efﬁcient L-form switch and growth. To test this, an
E. coli ST782 isolate from above was subjected to time-lapse
microscopy in the presence of phosphomycin, on media with
(Fig. 4a, Supplementary Movie 1) or without (Fig. 4b, Supple-
mentary Movie 2) osmoprotection. In the absence of osmopro-
tection the cells underwent several conventional divisions. They
then started to bulge, and all of the cells had lysed within 2.5 h. In
contrast, on osmoprotective media, after bulging, the cells
underwent a series of typically erratic L-form division events and
continued to grow in this state. The L-form transition was
completed within about 3 h of incubation.
To provide a source of recurrent infection L-forms would need
to be capable of returning back to the walled state in the absence
of antibiotic. To test this, we placed L-forms on osmoprotective
medium, without phosphomycin. Typical time-lapse imaging
results are shown in Fig. 4c and Supplementary Movie 3. The L-
forms initially went through several rounds of typical irregular
divisions. After 40 min, cells with an elongated shape and of
approximately normal diameter for walled cells began to appear.
Some of the L-forms contained appendages protruding in
different directions (Fig. 4c magenta arrow). The tubular cells
elongated and eventually began to divide by the classical binary
ﬁssion characteristic of walled cells. The initial L-form to rod
transition required only about 1.5 h of growth following with-
drawal of phosphomycin and after 5 h virtually all bacteria in the
ﬁeld of view had returned to the walled state. Similar results were
obtained for other strains, e.g. ST144 (Supplementary Movies 4, 5
and 6).
Urine supports L-form switching. L-form switching would only
be relevant to the clinical situation if the L-forms were viable in
urine or tissues. One of the concerns is whether those environ-
ments could provide sufﬁcient osmoprotection for L-form sur-
vival. The osmolality of urine of a healthy individual oscillates
between about 400 and 800mOsm/kg25,26, similar to that of the
osmoprotective media we use to grow L-forms (500 mOsm/l). To
test whether patient isolates have the potential to survive as
L-forms in urine, we placed walled ST144 bacteria on an agarose
pad made with the ﬁltered urine of a healthy individual supple-
mented with phosphomycin and observed the cells by time-lapse
microscopy. Supplementary Movie 7 shows that the bacteria were
able to switch into the L-form state, and that they could pro-
liferate, albeit less efﬁciently than in optimised L-form growth
media (most likely due to lower nutrient levels in urine). To test
cell viability and their potential to regenerate the wall, we placed
ST144 L-forms in liquid ﬁltered urine supplemented with phos-
phomycin and incubated overnight. The presence of intact L-
forms the next day was conﬁrmed by phase contrast microscopy
(Fig. 4d). The L-forms were plated on media with and without
osmoprotection and incubated at 37 °C for 24 h. A lawn of small
variable colonies emerged only on the osmoprotective plates
(Fig. 4e, f). Microscopic examination revealed predominantly
walled bacteria, though L-forms and intermediate types were also
observed (Fig. 4g). These bacteria could now grow well on non-
osmoprotective medium showing that they had switched back to
the walled state. These results demonstrate that L-forms of bac-
teria isolated from a patient with rUTI can survive in urine in the
presence of phosphomycin and are able to regenerate their cell
wall following antibiotic withdrawal (Fig. 4h). Rojas et al.27
recently showed that the Gram-negative outer membrane con-
tributes substantially to the mechanical stability of the cell, per-
haps explaining how well the L-forms appear to survive in urine.
L-forms can regenerate the cell wall in vivo. Transparent zeb-
raﬁsh (Danio rerio) larvae allow direct visualisation of bacteria at
the single cell level in a living higher organism. To look directly
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Fig. 2 L-form-like structures observed in the urine of various patients.
a–h Examples of fresh urine samples assessed by phase contrast
microscopy. Bundels typical of dividing L-forms (a, b). Magenta arrows in
(c) and (d) point to putative L-form bacteria associated with sluffed
eukaryotic cells; in (e) and (f) they point at crescent shaped bulges,
reminiscent of the outer membrane in L-forms of Gram-negative bacteria;
in (g) a possible intermediate stage between walled and L-form is marked;
and in (h), internal membrane vesicles are evident. i–k Examples of ﬁxed
samples assessed by ﬂuorescence in situ hybridisation (FISH). Patient
samples were ﬁxed with paraformaldehyde and stained with DAPI and a
ﬂuorescently labelled DNA probe against bacterial 16S rRNA (BAC 16S). To
show the speciﬁcity of DAPI and the probe staining an image was acquired
in the red channel, which did not produce signiﬁcant ﬂuorescence
(Control). i Two L-form-like structures were observed among several likely
walled bacteria. One of the objects stained both with the bacterial
probe and DAPI (magenta arrow) while the other one, only with DAPI (blue
arrow). j Example of L-form-like structures of varied size that stained with
the bacterial probe. k Example showing a eukaryotic cell in urine in the
same ﬁeld of view as numerous bacteria. The bacterial DNA and the
nucleous of the eukaryotic cell (n) both stained with DAPI but the BAC 16S
probe only associated with the bacterial cells, demonstrating the speciﬁcity
of the probe. Scale bars= 5 µm, apart form panel (k), where the scale
bar= 15 µm
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for L-form switching in vivo, a derivative of a ST144 E. coli isolate
expressing cytoplasmic YFP was injected into the tail ﬁn of zeb-
raﬁsh larvae at 3 days post fertilisation (dpf) in the absence
(Fig. 5a) or presence (Fig. 5b) of phosphomycin, and visualised
using phase contrast (PC) or ﬂuorescence (YFP) microscopy.
(Note that the striations observed in the phase contrast images are
cartilage structures of the larval tail ﬁn.) In the absence of anti-
biotic, most of the walled bacterial cells retained their rod shape
(Fig. 5a), although some occasionally became rounded (Fig. 5a,
magenta arrow). This morphological switching, which could
indicate progression to L-form or dying cells, could have occurred
spontaneously or have been due to the activity of host phagocytic
cells, such as neutrophils and macrophages, that damage the
bacterial cell wall. However, in the presence of phosphomycin,
switching to a characteristic L-form morphology occurred rapidly
(~30 min post infection) and in virtually all injected larvae
(Fig. 5b). Supplementary Fig. 2A and Supplementary Movie 8
show the progression of a rod-shaped bacterium (magenta arrow)
to a round shape over 40 min during the course of imaging.
Although some bacteria progressed to L-form faster than others,
these experiments showed that switching to the L-form can occur
rapidly in vivo in the presence of phosphomycin.
To test for L-form survival in vivo, ST144-YFP E. coli L-forms
induced in vitro with phosphomycin were injected into larvae in
the presence of the antibiotic, and visualised as described above.
In this case, L-forms were clearly visible immediately following
the injection as rounded entities of various sizes (Fig. 5c).
Moreover, many L-forms remained easily detectable following
overnight incubation (Fig. 5d), showing that long term survival of
cell-wall-deﬁcient bacteria is supported in the complex and
innate-immune-proﬁcient environment of zebraﬁsh larvae.
To further test whether L-form bacteria could survive in that
state in vivo, but also switch back into walled forms,
phosphomycin induced ST144-YFP L-forms were washed to
remove the antibiotic and then injected into larvae in the absence
of antibiotic; walled bacteria were injected into another set of
larvae as controls. The injection sites were visualised by
ﬂuorescence microscopy to verify the presence of bacteria 0, 4
and 20 h post infection (Fig. 5e–g). In parallel, bacteria were
recovered from larvae on NA medium (to detect walled cells)
(Fig. 5h)). For larvae injected with walled bacteria, microscopy
conﬁrmed the presence of rod-shaped bacteria at all time points,
and again rounded bacteria were occasionally observed (magenta
arrows) (Fig. 5e–g, walled). In agreement with this, walled
bacteria were consistently recovered at all time points tested
(Fig. 5h, walled). In the case of larvae injected with L-forms, no
CFU were detected at 0 and 4 h post infection (Fig. 5h, 0 h and
4 h, L-forms), even though L-forms were observed at those times
by microscopy (Fig. 5e, f, L-forms). However, bacterial colonies
started to emerge 20 h post infection (Fig. 5h, 20 h, L-forms) at
which point rod-shaped (i.e. walled) bacteria were also
detected by microscopy (Fig. 5g, L-forms). To test for switching
of L-forms in vivo, larvae injected with L-forms were visualised
using time-lapse microscopy following overnight incubation.
Supplementary Fig. 2B and Supplementary Movie 9 show a
rounded cell resembling an L-form followed over 30 min, during
which the bacterium changed shape from round into the
elongated shape characteristic of walled cells. Supplementary
Fig. 2C and Supplementary Movie 10 show another rod-shaped
Table 1 Recurrence of E. coli strains in patient UTI343 treated with phosphomycin (summary of results)
Donation CFU/ml routine
culture
L-forms observed Treatment for UTI Strains identiﬁed by routine
culture
Strains identiﬁed following
ﬁltration
1 7 × 104 YES A ST144
2 1 × 105 YES ST144 ST144
3 1 × 105 YES ST144 ST144
4 1 × 105 YES ST144
5 300 YES C ST144
ST782
ST144
ST782
6 CLEAR YES Pho
7 1 × 105 YES ST144
8 1 × 105 YES ST144 ST144
9 1 × 105 YES ST144
10 1 × 105 YES ST144
11 5 × 104 YES C ST144
ST782
ST782
12 ND ND ND ND ND
First column indicates donation number. Second column contains the number of E. coli bacteria detected in each sample by a routine clinical culture method. Column three indicates whether structures
reassembling L-forms were detectable by phase contrast microscopy in the urine samples immediately after they arrived at the lab. Column four shows whether the patient was treated with antibiotics
for UTI: A-amoxicillin, C-cephalexin, Pho-phosphomycin. Column ﬁve shows which strains were identiﬁed by MLST in the samples from routine culture. Column six shows which strains were identiﬁed by
MLST in the samples cultured following ﬁltration
ND not done (sample not provided for this study)
PC DAPI BAC 16S Control
a
c
b
Fig. 3 Examples of L-form-like structures observed in the patient UTI343
urine. a–c Example images taken before (a) and during (b, c) the treatment
with phosphomycin, assessed by phase contrast and FISH. Scale bar= 5 µm
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bacterium followed over 80 min in a separate region of the same
larva undergoing two rounds of division by binary ﬁssion,
characteristic of walled bacteria. Thus, L-forms can not
only survive for many hours in vivo, but also regenerate their
wall and resume normal growth and division in the zebraﬁsh
infection model.
Discussion
This pilot scale study of clinical samples has demonstrated that
L-forms are frequently present in the urine of a cohort of older
patients with rUTI. Although, many of these patients were treated
with cell-wall-active antibiotics this cannot explain their presence in
samples taken during periods with no antibiotic treatment. We have
recently shown that immune effectors such as lysozyme can actually
promote the L-form switch, at least for several Gram-positive
bacteria8. The occasional detection of rounded cells in the zebraﬁsh
experiments would be consistent with innate-immune generation of
L-forms. Although the zebraﬁsh model is useful for visualising the
walled to L-form transition in vivo, mammalian models will be
needed to characterise the possible role of the L-form in recurrent
infection going forward. Ultimately, larger scale trials focused spe-
ciﬁcally on culture negative patients treated with cell-wall-targeting
antibiotics will be required to directly establish the extent to which
L-form switching contributes to antibiotic evasion.
Aside from antibiotic evasion (discussed below) L-form bac-
teria may also beneﬁt from being less susceptible to innate-
immune killing than walled cells. Although they may still be
susceptible to other arms of the immune system, for example
antimicrobial peptides or immune response stimulated by LPS,
they presumably do not trigger innate-immune receptors speciﬁc
for cell-wall components7. Overall, it seems likely that the
immune stimulation by L-forms is less than that exerted by
walled bacteria. It is conceivable that L-forms can survive parti-
cularly well in immunocompromised or older patients.
One of the most signiﬁcant implications of this study is that,
along other mechanisms used by bacteria to recur, L-forms could
provide a source of bacterial survivors during treatment with cell-
wall-speciﬁc antibiotics, independent of the need to acquire speciﬁc
resistance genes (Fig. 4h). Instead, the antibiotic target (the cell wall)
is temporally removed and its requirement for survival bypassed.
Unlike previously described dormant persister cells4,5, L-forms can
continue to proliferate during what can be long (typically
5–14 days) periods of antibiotic treatment. Most importantly, we
directly show that L-form bacteria induced by the presence of
antibiotic in urine or zebraﬁsh larvae are able to revert to a walled
state once the antibiotic is removed. Beyond rUTI it now seems
plausible that L-form switching might be an underappreciated
mechanism of antibiotic tolerance by bacteria in other recurrent or
chronic infections9–14. Finally, our results suggest that effective
clearance of some recurrent infections might require the combi-
nation of cell-wall-targeting antibiotics with other classes of anti-
biotics, such as those targeting the bacterial membrane.
Methods
Patients. Urine samples were obtained from a pilot study of 30 geriatric (age 65 or
over) individuals with a history of recurrent UTI, run under ethical approval of the
Newcastle Research Ethics Committee (reference REC-14-NE-0026)15. Patients
were recruited with written informed consent through UTI clinics led by the
Urology Department at Freeman Hospital, Newcastle upon Tyne, UK. Volunteers
were from either weekly UTI clinics led by the Urology Department at the Freeman
Hospital, Newcastle-upon-Tyne or the organisation VoiceNorth (www.voicenorth.
org). Inclusion criteria stated that patients were community dwelling and needed to
have had two or more symptomatic UTIs as noted in their clinical records.
Exclusion criteria speciﬁed evidence of complicated UTI such as catheter use.
The samples were donated every 2 weeks for a period of 6 months and screened
in an unbiased manner with respect to clinical data. The study was designed such
that patients should provide both symptomatic and non-symptomatic samples, the
latter serving as internal controls.
Bacterial strains and growth conditions. CPS Elite diagnostic plates (BioMer-
ieux) or L-form media (LM) supplemented with 0.2% agarose were used for initial
culture of bacteria from urine samples. LM media contained 1x Brian Heart
Infusion (BHI) supplemented with 0.5 M sucrose and 8 mM MgSO4. For growth of
isolated ST144 and ST782 E. coli strains, ST144-YFP and laboratory E. coli strain
BW25113 nutrient broth (NB, Oxoid) or nutrient agar (NA, Oxoid) was used as
non-osmoprotective medium and liquid L-form medium (LM) or supplemented
0′ 40′ 80′ 120′ 160′
Osmoprotection + phosphomycin
a
0′
No osmoprotection + phosphomycin
40′ 80′ 120′ 160′
0′
200′ 240′ 280′ 320′ 360′
40′ 80′ 120′ 160′
Osmoprotection
b
c
e f g
+ Osm– OsmUrine + Osm
d
Antibiotic treatment After treatmentBefore treatment
h
Fig. 4 E. coli transition from rod to L-form and back on osmoprotective
medium and in urine. Magenta arrows indicate individual bacteria, which
were followed in time lapse and described in details in the main text.
a Transition of strain ST782 from walled to L-form on osmoprotective
medium (LM: L-form media) in the presence of 0.4mg/ml phosphomycin.
b Growth of strain ST782 in the presence of 0.4mg/ml phosphomycin on
non-osmoprotective medium (NA: nutrient agar). c ST782 transition from
L-form to walled on osmoprotective medium (LM) after phosphomycin was
removed. Time lapse over 5 h. Forty-minute increments are shown on the
left-hand side of each image. d–g Survival of L-forms in urine and reversion
to the walled state. d Phase contrast image of ST144 L-forms, which
survived in urine overnight in the presence of phosphomycin. Viability of L-
forms in urine was demonstrated by plating on NA (e) and LM (f). Growth
was detectable only on osmoprotective medium (f) after 24 h incubation at
37 °C. g Microscopic appearance of bacteria detected in (f). h Model
showing L-form switching as a mechanism for the recurrence of bacterial
infections. Bacteria causing UTI are treated with cell-wall-targeting
antibiotics. This leads to elimination of the cell wall and emergence of
L-forms, which are not detectable by standard clinical culture methods.
Following antibiotic treatment the bacteria can regenerate the wall and
potentially cause recurrence of a full-blown infection. The bacterial cell wall
is indicated with dark purple lines. Panel (h) was created by Katarzyna
Mickiewicz. Scale bars= 5 µm
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with agarose at 0.2 or 1% as indicated, were used for osmoprotection. Fresh urine
of a healthy individual passed through a 0.2 µm cut off ﬁlter (supplemented with
0.2% agarose for time-lapse microscopy) was used for urine survival assays.
Phosphomycin was added at 400 µg/ml where indicated. The cultures were incu-
bated at 37 or 30 °C as indicated. yfp plasmid PMCL20028 was introduced to
electrocompetent ST144 cells by electroporation at 2.5 µF, 200Ω, 2.5 V in a Gene
Pulser Xcell electroporation unit (Bio-Rad) to create strain ST144-YFP.
Urine processing. Urine processing and scoring for the presence of L-forms was
blinded. Fresh urine samples obtained from patients were streaked using 10 µm
loops on CPS Elite plates and incubated overnight at 37 °C. Aliquots of 2 ml were
ﬁltered through 0.45 µm cut off ﬁlters onto 5 ml of LM medium in 30 ml universal
tubes, supplemented with 0.2% agarose and incubated at 30 °C for up to 1 month.
Samples cultured in semi-liquid medium were re-streaked on NA plates and single
colonies were picked for 16S rRNA sequencing. For patient UTI343, 20 colonies
were subjected to MLST sequencing prior to and after ﬁltration. Samples of fresh
urine (500 µl) were concentrated 20× by centrifugation at 8000 × g for 2 min and a
1 µl volume from each sample was examined immediately by phase contrast
microscopy. Samples of 250 µl urine were ﬁxed with 4% paraformaldehyde, fol-
lowed by overnight incubation at 4 °C. Paraformaldehyde was removed and the
samples were stored in 50% ethanol/50% PBS at −20 °C.
Zebraﬁsh injections. All zebraﬁsh experiments were performed using wild-type
AB zebraﬁsh. Eggs were obtained from naturally spawning zebraﬁsh and embryos
were reared in Petri dishes, at 28.5 °C in embryo medium (0.5X E2) supplemented
with 0.3 µg/ml methylene blue29. For injections and live imaging, 3 days post
fertilisation (dpf) larvae were anaesthetised with 200 µg/ml tricaine (Sigma-
Aldrich) in embryo medium. During in vivo microscopy, larvae were maintained in
a b
c d
PC YFP
h
Walled Walled L-forms Walled L-forms
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e f g
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Fig. 5 L-form switching in the zebraﬁsh embryo. a, b Walled E. coli ST144-YFP was injected into the tail ﬁn of zebraﬁsh larvae in the presence (b) or
absence (a) of 0.4 mg/ml phosfomycin and visualised by phase contrast (PC) or ﬂuorescence microscopy (YFP). The magenta arrow in (a) points to a
bacterium that appears to have adopted a round shape in the absence of antibiotic. c, d ST144-YFP E. coli L-forms induced in vitro with 0.4mg/ml
phosfomycin were injected into the tail ﬁns of zebraﬁsh larvae in the presence of 0.4 mg/ml phosfomycin and visualised by microscopy immediately post-
injection (c), or following an overnight incubation (d). e–g ST144-YFP E. coli walled or in vitro induced L-form bacteria were injected in the absence of the
antibiotic and visualised 0 h (e), 4 h (f) or 20 h (g) post infection. h The bacteria were enumerated by homogenising ﬁsh embyos and plating out on NA 0,
4 or 20 h post infection. Each circle represents recovered bacteria from an individual larva. Representative data from two independent experiments (one
with two and one with three larvae). Mean (horizontal bars) is shown. The p values were determined by non-parametric Mann–Whitney test. Signiﬁcance
was deﬁned as p < 0.05. Scale bars= 5 µm. Source data for Fig. 5h are provided as Source Data ﬁle
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a 33 °C atmosphere, for optimal conditions for bacterial replication. Bacterial strain
ST144-YFP was cultured overnight in liquid NB, supplemented with 30 µg/ml
chloramphenicol, and sub-cultured to exponential phase (ODA600= 0.6). For L-
forms injections, sub-cultures in NB were supplemented with 0.4 mg/ml phos-
phomycin. To prepare the inoculum for injection, the suspension was centrifuged
for 4 min at 4000 × g, washed and resuspended in PBS to 10,000 CFU/nl. Larvae
were injected with 1–2 nl of bacterial suspension in the tail ﬁn. For induction of L-
forms in vivo, 0.4 mg/ml phosphomycin was injected intravenously (1 nl) and
added to the embryo medium containing anaesthetic. Larvae were sacriﬁced in
tricaine and mechanically disrupted in LM liquid media at the indicated time
points. For recovery experiment (Fig. 5c), homogenates were serially diluted and
plated onto NA, supplemented with 30 µg/ml chloramphenicol, to recover rod
bacteria. Each circle represents recovered bacteria from an individual larva (two
independent experiments, one with two and one with three larvae).
Ethics statements. Animal experiments were performed according to the Animals
(Scientiﬁc Procedures) Act 1986 and approved by the Home Ofﬁce (Project
licences: PPL P84A89400 and P4E664E3C). All experiments were conducted up to
5 days post fertilisation.
Sequencing. Genomic DNA of bacteria isolated following ﬁltration was extracted
using a DNeasy Blood and Tissue kit (Qiagen) and subjected to sequencing with
the following pairs of primers:
16S rRNA (performed on all samples):30
E334F forward CCAGACTCCTACGGGAGGCAGC
E1115R reverse AGGGTTGCGCTCGTTG
MLST (performed on E.coli strains isolated from patient UTI343):31
adenylate kinase:
adk_forward ATTCTGCTTGGCGCTCCGGG
adk_reverse CCGTCAACTTTCGCGTATTT
fumarate hydratase:
fumC_forward TCACAGGTCGCCAGCGCTTC
fumC_reverse GTACGCAGCGAAAAAGATTC
DNA gyrase:
gyrB_forward TCGGCGACACGGATGACGGC
gyrB_reverse ATCAGGCCTTCACGCGCATC
isocitrate/isopropylmalate dehydrogenase:
icd_forward ATGGAAAGTAAAGTAGTTGTTCCGGCACA
icd_reverse GGACGCAGCAGGATCTGTT
malate dehydrogenase:
mdh_forward ATGAAAGTCGCAGTCCTCGGCGCTGCTGGCGG
mdh_reverse TTAACGAACTCCTGCCCCAGAGCGATATCTTTCTT
adenylosuccinate dehydrogenase:
purA_forward CGCGCTGATGAAAGAGATGA
purA_reverse CATACGGTAAGCCACGCAGA
ATP/GTP binding motif:
recA_forward CGCATTCGCTTTACCCTGACC
recA_reverse TCGTCGAAATCTACGGACCGGA
Microscopy imaging. For snapshot live-cell imaging, urine or cells were mounted
on microscope slides directly or on 1% agarose in water, NB or LM. For time-lapse
imaging, cells were placed in 25 µl Gene Frames (Thermo Fisher) on 0.2 or 0.5%
agarose in NB, LM or urine. The slides were placed on the microscope stage at 30 °C.
Images were acquired with a Rolera EM-C2 (Q-imaging) camera attached to a Nikon
TiE microscope, and analysed using Metamorph (Molecular Devices). For zebraﬁsh
imaging, embryos were embedded in 1% low-melting-point agarose in 35mm dia-
meter glass-bottom MatTek dishes. In vivo time lapses were acquired using Zeiss
LSM 880 and ×63 oil immersion objective. Pictures and videos were prepared for
publication using ImageJ. Representative images were included in the ﬁgures.
Fluorescence in situ hybridisation (FISH). Fixed samples from the frozen at
−20 °C were thawed and serially dehydrated with 60, 80 and 100% ethanol fol-
lowed by hybridisation with a FISH probe speciﬁc for bacterial 16S rRNA: BAC 16S
GCTGCCTCCCGTAGGAGT (referred to as EUB338 in ref. 32) at 46 °C for 4 h in a
hybridisation buffer containing 1M NaCl, 20 mM Tris-HCl, pH 7.5, 0.1% SDS and
20% formamide. Following hybridisation, the probes were placed in wash buffer
containing 1M NaCl, 20 mM Tris-HCl, pH 7.5, 0.1% SDS and incubated for
15 min at 48 °C. The wash was repeated 2×. After washing, samples were resus-
pended in 10 µl water, placed on a 1% agarose water pad containing 1 µl/ml DAPI
and visualised by ﬂuorescence microscopy.
Urine survival assay. ST144 bacteria were streaked on LM plates containing
phosphomycin and incubated overnight at 30 °C. The resulting L-forms were
placed the next day in fresh ﬁltered urine containing phosphomycin and incubated
overnight at 37 °C. The following day, integrity of the L-forms was assessed by
phase contrast microscopy and the culture OD600 was adjusted to 0.5. Hundred
microliters of samples were plated on NA or LM plates and incubated for 24 h at
37 °C. Emerging colonies were examined by phase-contrast microscopy.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
16S rRNA and MLST data are available at GenBank with accession numbers provided in
Supplementary Data 1. The source data underlying Fig. 5H are provided as a Source
Data ﬁle.
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